FDA Grants Early Approval to Viridian’s Lumvoa for Thyroid Eye Disease

Key Facts

In a move that reshapes the competitive landscape for rare disease treatments, Viridian Therapeutics received early FDA approval for Lumvoa (VRDN-001) to treat thyroid eye disease (TED). The decision grants the company a clear labeling advantage over Amgen’s Tepezza, thanks to a shorter infusion time and the inclusion of chronic TED data on the label. The drug is immediately available to patients, according to media reports.

The approval arrives as the TED treatment market expands rapidly, with Tepezza having captured significant market share since its launch. Although management has tempered near-term revenue expectations for Lumvoa, the label advantage could help Viridian carve out market share, particularly as physicians seek faster and more comprehensive treatment options. Per market data, Amgen has not announced any immediate competitive response.